Related Experiment Video
Updated: Jul 2, 2026

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma
Published on: May 24, 2024
Yttrium-90 microsphere induced gastrointestinal tract ulceration
Christopher D South1, Marty M Meyer, Gregory Meis
1Division of Gastroenterology, Hepatology, and Nutrition; The Ohio State University Medical Center, Columbus, Ohio, USA.
Gastrointestinal bleeding is a rare but serious complication of yttrium-90 (90Y) microsphere therapy for liver cancer. Refractory ulcers require aggressive surgical management to prevent potentially fatal outcomes.
Area of Science:
- Interventional Radiology
- Hepatobiliary Oncology
- Gastroenterology
Background:
- Radiomicrosphere therapy (RT) with yttrium-90 (90Y) microspheres is an established regional treatment for hepatic malignancies.
- This study investigates the incidence and severity of gastrointestinal (GI) complications following RT at a major academic institution.
Observation:
- A review of 27 patients undergoing RT between 2004 and 2007 identified three cases of GI bleeding.
- Angiographic review revealed varied vascular anatomies, and none of the affected patients had prophylactic gastroduodenal artery embolization.
- Endoscopic findings included erythema, mucosal erosions, and persistent gastric ulcers, with microspheres visible on biopsy.
Findings:
- Gastrointestinal ulceration is a rare complication of 90Y microsphere embolization.
- Complications can be severe, leading to persistent ulcers and, in one case, death from hemorrhage despite medical management.
- Prophylactic embolization of the gastroduodenal artery was not performed in the identified cases.
Implications:
- Gastrointestinal ulceration following RT, though infrequent, carries significant risks.
- Aggressive surgical intervention should be considered for refractory ulcers post-RT.
- Further research into prophylactic measures may be warranted to mitigate GI complications.
Related Concept Videos
Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
Peptic Ulcer Disease IV: Management
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current medication...
Peptic Ulcer Disease I: Introduction
An acute ulcer, marked by superficial erosion and minimal inflammation, swiftly resolves upon identifying and addressing the underlying cause. In contrast, a chronic ulcer persists, potentially eroding through the muscular wall and forming fibrous tissue.
Peptic ulcers can also be...
Peptic Ulcer Disease I: Introduction
Peptic Ulcer Disease II: Pathophysiology
Peptic Ulcer Disease II: Pathophysiology
Damaging agents such as Helicobacter pylori, gastric acid, pepsin, and nonsteroidal anti-inflammatory drugs (NSAIDs) can weaken the mucosal defense, allowing hydrogen ions to infiltrate back and harm epithelial cells.
